Evidence map›Paper›PMID 33850305›Full record

ArticleCancer gene therapy2022

Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts.

Prakash Ambady, Yingjen Jeffrey Wu, Cymon N Kersch, Joshua M Walker, Samantha Holland, Leslie L Muldoon, Edward A Neuwelt

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Targeted gene therapy for cancer: the impact of microRNA multipotentiality.Medical oncology (Northwood, London, England) · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Prakash Ambady *Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA. ambady@ohsu.edu.
Yingjen Jeffrey Wu *Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Cymon N KerschDepartment of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Joshua M WalkerDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Samantha HollandDepartment of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Leslie L MuldoonDepartment of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Edward A NeuweltDepartment of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
Oregon Health & Science University · USPortland VA Medical Center · US

Funding

Two Compartment Models to Improve Brain Tumor TherapyR01CA137488 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI NEUWELT, EDWARD A. · 2008 to 2019
$7.3M
Opening of the Blood-Brain Barrier to Antitumor AgentsR01CA199111 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI NEUWELT, EDWARD A. · 2016 to 2020
$3.1M
NCI NIH HHS R01 CA137488NCI NIH HHS R01 CA199111
6 · The paper itself

Abstract

Overexpression of O

Indexed as

Brain NeoplasmsCerebellar NeoplasmsMedulloblastomaAnimalsAntineoplastic Agents, AlkylatingCell Line, TumorHeterograftsHumansMorpholinosO(6)-Methylguanine-DNA MethyltransferaseOligonucleotides, AntisenseRatsRats, Long-EvansXenograft Model Antitumor AssaysAntineoplastic Agents, AlkylatingMorpholinosO(6)-Methylguanine-DNA MethyltransferaseOligonucleotides, Antisense

Identifiers

PMID33850305
PMCPMC9113935
OpenAlexW3155212507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.